Device for myocardial infarction management, comprises: low-level laser therapy unit, tunable unit housing control system, power adapter and adjuster section, computational processing module, probe assembly, control interface configured to enable real-time adjustment of treatment parameters
	MOHANTY S; SAHU S S; PATTNAIK A K; MUKHERJEE T
	2024-03-27
专利权人	BIRLA INST TECHNOLOGY MESRA (BIRL-Non-standard)
申请日期	2024-03-27
专利号	IN202431024417-A
成果简介	NOVELTY - Device comprises: (a) a low-level laser therapy (LLLT) unit configured to emit infrared radiation at a wavelength in the range of 1550-1600 nm, where the wavelength is derived from resonant recognition model (RRM) analysis of vascular endothelial growth factor A (VEGF-A) and VEGF-A receptor (VEGFR) interactions to restore optimal electron energy distribution and activate angiogenic pathways; (b) a tunable unit housing a control system, where the control system comprises a console featuring a settings selection screen to enable precise adjustment of treatment parameters based on myocardial infarct location and severity; (c) a power adapter and adjuster section operably connected to the LLLT unit to regulate power output, energy density, pulsation mode, and beam profile; (d) a computational processing module configured to analyze VEGF-A and VEGFR interactions using RRM. USE - Device for myocardial infarction management. ADVANTAGE - The device activates specific protein receptor interactions for targeted treatment of post-myocardial infraction (MI), thus accelerating the development of new blood vessels, improves infarct healing and reverses cardiac hypertrophy pathology. DETAILED DESCRIPTION - Device comprises: (a) a low-level laser therapy (LLLT) unit configured to emit infrared radiation at a wavelength in the range of 1550-1600 nm, where the wavelength is derived from resonant recognition model (RRM) analysis of vascular endothelial growth factor A (VEGF-A) and VEGF-A receptor (VEGFR) interactions to restore optimal electron energy distribution and activate angiogenic pathways; (b) a tunable unit housing a control system, where the control system comprises a console featuring a settings selection screen to enable precise adjustment of treatment parameters based on myocardial infarct location and severity; (c) a power adapter and adjuster section operably connected to the LLLT unit to regulate power output, energy density, pulsation mode, and beam profile; (d) a computational processing module configured to analyze VEGF-A and VEGFR interactions using RRM, where the module applies fast fourier transform (FFT) and stockwell transform (ST) to identify characteristic frequencies and refine interaction hotspots for targeted stimulation; (e) a probe assembly operably coupled to the LLLT unit, where the probe assembly comprises a photon delivery interface with a variable aperture to facilitate controlled emission and focusing of infrared radiation to the infarcted cardiac tissue region; and (f) a control interface configured to enable real-time adjustment of treatment parameters, including pulse energy, repetition rate, pulse frequency, duration, continuous energy, modulation modes, and beam diameter, where the parameters are dynamically optimized based on computational analysis and real-time monitoring of angiogenic response to enhance therapeutic efficacy while minimizing adverse effects. An INDEPENDENT CLAIM is included for a method for myocardial infarction management utilizing the device, comprising: (a1) performing a computational analysis of VEGF-A and VEGFR interactions utilizing RRM, where the analysis includes collecting and preparing protein sequences of VEGF-A ligands and VEGFR receptors from databases, converting amino acid sequences into numerical sequences using electron ion interaction potential (EIIP) values, applying FFT to the numerical sequences to identify characteristic frequencies related to VEGF-A and VEGFR interactions, and refining interaction hotspots using ST and signal processing techniques to localize frequencies in both time and frequency domains; (b1) configuring an LLLT device to emit infrared radiation at a wavelength of 1570 nm, where the wavelength is derived from RRM analysis to restore optimal electron energy distribution and activate angiogenic pathways; (c1) positioning a photon delivery probe over the infarcted cardiac tissue region to direct the emitted infrared radiation at a controlled energy density and pulse frequency; (d1) adjusting treatment parameters via a control interface, where the treatment parameters include pulsation mode, power output, repetition rate, duration, pulse energy, continuous energy, modulation settings, and beam diameter; (e1) applying the configured LLLT treatment to the infarcted region for a predetermined duration based on computationally derived optimal exposure levels; (f1) monitoring angiogenic response post-therapy to assess therapeutic efficacy and adjust subsequent treatment sessions accordingly; and (g1) adaptively modifying treatment parameters based on real-time monitoring data to optimize outcomes and minimize adverse effects.
IPC 分类号	A61B-005/024 ; A61B-005/11 ; A61N-005/06 ; A61P-009/00 ; G16H-040/67
国家	印度
专业领域	信息技术
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/17512
专题	中国科学院新疆生态与地理研究所
作者单位	BIRLA INST TECHNOLOGY MESRA (BIRL-Non-standard)
推荐引用方式 GB/T 7714	MOHANTY S,SAHU S S,PATTNAIK A K,et al. Device for myocardial infarction management, comprises: low-level laser therapy unit, tunable unit housing control system, power adapter and adjuster section, computational processing module, probe assembly, control interface configured to enable real-time adjustment of treatment parameters. IN202431024417-A[P]. 2024.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。